AARTIPHARM.BOAARTIPHARM.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +19.86% | +11.47% | -30.48% | -8.67% | -19.62% |
| Gross Profit Growth | +28.50% | +34.09% | +37.34% | -36.89% | -1.09% |
| EBITDA Growth | +37.69% | +20.90% | -3.68% | -23.83% | -22.13% |
| Operating Income Growth | +37.28% | +24.81% | -5.04% | -31.38% | -30.20% |
| Net Income Growth | +40.23% | +35.38% | -10.73% | -48.88% | -35.18% |
| EPS Growth | +40.21% | +35.42% | -10.78% | -48.92% | -35.17% |
| EPS Diluted Growth | +40.21% | +35.28% | -10.78% | -48.84% | -35.17% |
| Weighted Average Shares Growth | +0.02% | +0.06% | +0.06% | +0.06% | -0.02% |
| Weighted Average Shares Diluted Growth | +0.02% | +0.08% | +0.06% | -0.10% | -0.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +8.46% | +0.00% | +8.34% | +0.00% |
| Inventory Growth | +0.00% | -8.60% | +0.00% | -13.78% | +0.00% |
| Asset Growth | +0.00% | +12.56% | +0.00% | +17.63% | +0.00% |
| Book Value per Share Growth | +12.00% | +13.19% | +13.19% | +10.14% | +0.00% |
| Debt Growth | +0.00% | +44.82% | +0.00% | +70.46% | +0.00% |
| R&D Expense Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +15.13% | -55.63% | -100.00% | +139.67% | -100.00% |